Basilea opts not to take MRSA antibiotic into clinic due to ‘stringent risk-return criteria’
Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason for not taking up its option to bring an MRSA antibiotic into clinical development.
Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason for not taking up its option to bring an MRSA antibiotic into clinical development.
